Lung Cancer
Avelumab Maintenance With Axitinib Interruption Feasible in Kidney Cancer
Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to updated phase 2 TIDE-A study results.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Proactive Onco-Coaching Improves Survival in Metastatic Kidney Cancer
Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic renal cell carcinoma.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
Relugolix Shows Strong Adherence in Medicare Patients With Prostate Cancer
Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen deprivation therapy, per real-world study data.
Avelumab Maintenance Therapy Enhances Survival in Advanced Urothelial Cancer
Avelumab plus best supportive care improved survival vs best supportive care alone in advanced urothelial carcinoma, regardless of diabetes status.